Skip to main content
An official website of the United States government

RAS Dialogue Blog

Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.

    • The RASopathies Network
      , by Lisa Schoyer and Beth Stronach

      RASopathies are neurodevelopmental genetic syndromes caused by germline mutations in RAS pathway genes that result in increased MAPK signaling. The RASopathies Network provides an umbrella organization to connect affected families with researchers.

      Continue Reading >

    • Intravenous High-Dose Vitamin C in Cancer Therapy
      , by Lewis Cantley and Jihye Yun

      Pharmacologic levels of vitamin C in plasma can only be achieved by intravenous administration. Vitamin C undermines RAS-mutant cells’ reliance on upregulation of glycolysis and antioxidant activities to support their cancer lifestyle.

      Continue Reading >

    • Taking RAS Research to Space
      , by Albert Chan

      High-quality crystal structures of RAS are essential for developing new drugs for this difficult target. Crystals of RAS protein grown on the International Space Station had improved qualities compared to those grown in earth gravity.

      Continue Reading >

    • The Role of Mitochondrial Dynamics in Ras-driven Cancers
      , by David Kashatus

      Mitochondria are dynamic structures that respond to the metabolic needs of cells. The altered metabolism of cells driven by oncogenic KRAS genes results in mitochondrial fission. Blocking mitochondrial fission limits transformation and tumor growth.

      Continue Reading >

    • Covalent Inhibitors of RAS
      , by Anna Maciag

      A “tethered screening” approach is opening new doors to drugging RAS proteins. The NCI RAS Initiative is developing small molecules that covalently modify cysteine-185 and histidine-95 of KRAS.

      Continue Reading >

Archive

Email